Zydus receives approval from USFDA for Acetazolamide ER Capsules

Zydus receives approval from USFDA for Acetazolamide ER Capsules

Zydus Cadila has received the final approval from the USFDA to market Acetazolamide ER Capsules (US RLD – Diamox). It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used to treat certain types of glaucoma (caused by increased ocular pressure) and to treat or prevent altitude sickness (acute mountain sickness). The group now has 246 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.